What's new in diabetes: incretins and C-peptide.

Med Princ Pract

University of Surrey, Guildford, UK. vincentmarks @ btinternet.com

Published: May 2011

Download full-text PDF

Source
http://dx.doi.org/10.1159/000321278DOI Listing

Publication Analysis

Top Keywords

what's diabetes
4
diabetes incretins
4
incretins c-peptide
4
what's
1
incretins
1
c-peptide
1

Similar Publications

Background: Diabetic chronic foot ulcers pose a significant therapeutic challenge around the world, resulting in adverse effects and complications in patients. D-mannose is enriched in cirtus peel and exerts beneficial effects among various diseases, especially against inflammation-related disorders.

Methods: Here, we examined the potential effect of D-mannose during wound healing process in streptozotocin (STZ)-induced diabetes mice in vivo and by culturing keratinocytes under high glucose condition in vitro.

View Article and Find Full Text PDF

From immunoglobulin A nephropathy to primary focal segmental glomerulosclerosis, sparsentan expands its indications. Complement inhibitors offer new hope for patients with certain poor-prognosis glomerulonephritides. Semaglutide enjoys great success, promising nephro- and cardioprotection for type 2 diabetics.

View Article and Find Full Text PDF

[Hypertension : what's new in 2024].

Rev Med Suisse

January 2025

Service de néphrologie et d'hypertension, Centre hospitalier universitaire vaudois, 1005 Lausanne.

The major clinical studies in 2024 reviewed in this manuscript will focus on blood pressure measurement, the effect of coffee on the latter, its follow-up in the postpartum period, blood pressure targets for patients at high cardiovascular risk, particularly those with diabetes, and the late onset of primary aldosteronism after a negative initial confirmation test.

View Article and Find Full Text PDF

[Diabetology : what's new in 2024].

Rev Med Suisse

January 2025

Service d'endocrinologie et diabétologie, Hôpitaux universitaires de Genève, 1211 Genève 14.

Diabetology is a continuously evolving discipline, many molecules are developed, and treatment recommendations change regularly according to the latest published studies. After lifestyle measures that must always be preferred before any drug, metformin remains the pharmacological basis of treatment. Current recommendations favor the introduction of an SGLT2 inhibitor or a GLP-1 receptor agonist after metformin because these molecules have shown beneficial cardiovascular and renal effects.

View Article and Find Full Text PDF

Sepsis-associated acute kidney injury (SA-AKI) is defined as the development of AKI in the context of a potentially life-threatening organ dysfunction attributed to an abnormal immune response to infection. SA-AKI has been associated with increased mortality when compared to sepsis or AKI alone. Therefore, its early recognition is of the utmost importance in terms of its morbidity and mortality rates.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!